ECSP22050840A - Nuevos compuestos farmac?uticos - Google Patents

Nuevos compuestos farmac?uticos

Info

Publication number
ECSP22050840A
ECSP22050840A ECSENADI202250840A ECDI202250840A ECSP22050840A EC SP22050840 A ECSP22050840 A EC SP22050840A EC SENADI202250840 A ECSENADI202250840 A EC SENADI202250840A EC DI202250840 A ECDI202250840 A EC DI202250840A EC SP22050840 A ECSP22050840 A EC SP22050840A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compounds
new pharmaceutical
new
tuberculosis
prevention
Prior art date
Application number
ECSENADI202250840A
Other languages
English (en)
Inventor
Pedro Silva Serra Joao
Patricia Da Costa Pereira Rosa Carla
Ferreira Ana L?Cia Almeida
Carlos Ramos Damil Joao
Homem E Sousa Dos Santos Sara Alexandra Marques
Vanessa Cordeiro Simoes Ana
Neves Rita Isabel Gomes
Filipe Augusto Eugenio Pardal
Original Assignee
Tecnimede Soc T?Cnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc T?Cnico Medicinal Sa filed Critical Tecnimede Soc T?Cnico Medicinal Sa
Publication of ECSP22050840A publication Critical patent/ECSP22050840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgaci?n se refiere a derivados de 6-sustituida quinolina-2-piperidina para su uso en el tratamiento y/o la prevenci?n de la tuberculosis.
ECSENADI202250840A 2019-12-27 2022-07-04 Nuevos compuestos farmac?uticos ECSP22050840A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PT11602819 2019-12-27
EP20163200 2020-03-13
PT11616820 2020-03-13
PCT/IB2020/062483 WO2021130732A1 (en) 2019-12-27 2020-12-28 Antibacterial quinolines

Publications (1)

Publication Number Publication Date
ECSP22050840A true ECSP22050840A (es) 2022-08-31

Family

ID=74554188

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202250840A ECSP22050840A (es) 2019-12-27 2022-07-04 Nuevos compuestos farmac?uticos

Country Status (17)

Country Link
US (1) US20230106913A1 (es)
EP (1) EP4081304B1 (es)
JP (1) JP2023508475A (es)
KR (1) KR20220122649A (es)
CN (1) CN114867528B (es)
AU (1) AU2020414492A1 (es)
BR (1) BR112022012704A2 (es)
CA (1) CA3162532A1 (es)
CL (1) CL2022001736A1 (es)
CO (1) CO2022009810A2 (es)
EC (1) ECSP22050840A (es)
GE (1) GEP20247590B (es)
IL (1) IL294363A (es)
MX (1) MX2022008005A (es)
PE (1) PE20221725A1 (es)
WO (1) WO2021130732A1 (es)
ZA (1) ZA202208089B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
EP2173346A2 (en) * 2007-06-27 2010-04-14 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
MX2010009643A (es) 2008-03-07 2010-09-22 Hoffmann La Roche Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
MX2013000748A (es) 2010-08-27 2013-03-05 Gruenenthal Gmbh 2-amino-quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
US20160113919A1 (en) 2014-10-22 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Chloroquine stereoisomer for treating tuberculosis related diseases
MX2017016788A (es) 2015-07-02 2018-07-06 Janssen Sciences Ireland Uc Compuestos antibacterianos.
US10329257B2 (en) * 2015-08-13 2019-06-25 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
WO2019243971A1 (en) * 2018-06-17 2019-12-26 Foundation For Neglected Disease Research Novel compounds and their methods of use thereof

Also Published As

Publication number Publication date
EP4081304C0 (en) 2024-03-06
GEP20247590B (en) 2024-02-12
WO2021130732A1 (en) 2021-07-01
KR20220122649A (ko) 2022-09-02
CA3162532A1 (en) 2021-07-01
BR112022012704A2 (pt) 2022-09-06
IL294363A (en) 2022-08-01
PE20221725A1 (es) 2022-11-04
CO2022009810A2 (es) 2022-08-09
EP4081304B1 (en) 2024-03-06
AU2020414492A1 (en) 2022-08-18
CL2022001736A1 (es) 2023-02-17
MX2022008005A (es) 2022-07-21
EP4081304A1 (en) 2022-11-02
JP2023508475A (ja) 2023-03-02
ZA202208089B (en) 2024-01-31
CN114867528A (zh) 2022-08-05
CN114867528B (zh) 2024-03-19
US20230106913A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020003714A2 (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
SV2018005610A (es) Derivados de oxopiridina sustituidos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP22050840A (es) Nuevos compuestos farmac?uticos
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas